scholarly journals Histomorphological view of the cornea investigated by laser confocal microscopy in keratoplasty

2022 ◽  
pp. 110-117
Author(s):  
D. A. Krakhmaleva ◽  
Z. V. Surnina ◽  
S. A. Malzhoen ◽  
A. A. Gamidov

Introduction. Corneal transplantation is the most successful and commonly performed allotransplantation procedure as compared with other organs and tissues. Over 100,000 corneal transplantations are performed worldwide every year.Purpose. This study investigated whether in vivo confocal microscopy (IVCM) can aid in the diagnosis of a graft rejection reaction by detecting changes in cellular structures and density of immune cells after penetrating keratoplasty.Materials and methods. The study included thirty-four eyes of 34 patients who underwent penetrating keratoplasty (7 eyes with corneal graft rejection, 27 without rejection). The average age of patients is 51.1 ± 13.6 years (from 23 to 76 years). The follow-up period ranged from 12 to 36 months (24.5 ± 4.84 months). Follow-up was performed at 1, 3, 6, 12 months and annually after PKP. To study the morphology of the cornea all patients underwent IVCM to assess the basal epithelium, subbasal layer, stroma and endothelium. Immune cells were identified and evaluated for the shape, length of the processes and their density.Results. Patients with corneal graft rejection demonstrated significant accumulation of corneal dendritic-like immune cells compared to patients with non-rejected grafts. In addition, the cells acquired a more mature morphology (grade 2–3). The density of dendritic cells (DC) was 809.17 ± 342.19 (p < 0.001). A positive correlation was found between DC density and graft rejection (p < 0.001). As well the patients showed signs of endothelial failure with low endothelial cell density and pleomorphism, increased light scattering and hyperreflectivity of the stroma.Conclusions. In a complex of diagnostic measures, confocal microscopy may provide a valuable clinical adjunctive tool in diagnosis and management of early corneal graft rejection.

2019 ◽  
Vol 203 ◽  
pp. 26-36 ◽  
Author(s):  
Chareenun Chirapapaisan ◽  
Alessandro Abbouda ◽  
Arsia Jamali ◽  
Rodrigo T. Müller ◽  
Bernardo M. Cavalcanti ◽  
...  

Cornea ◽  
2015 ◽  
Vol 34 ◽  
pp. S61-S64 ◽  
Author(s):  
Viridiana Kocaba ◽  
Caterina Colica ◽  
Muriel Rabilloud ◽  
Carole Burillon

2020 ◽  
Vol Volume 14 ◽  
pp. 3495-3498
Author(s):  
Omar M. Said ◽  
Mohamed G.A. Saleh ◽  
Ahmed F. Omar ◽  
Ahmed A. Abdou ◽  
Ali Natag Riad Mostafa

2020 ◽  
pp. 112067212093950
Author(s):  
Hua-Hsuan Kuo ◽  
Elizabeth P Shen

Purpose: To evaluate the safety and efficacy of 1% topical bevacizumab (10 mg/mL) on newly formed corneal neovascularization (NV) after penetrating keratoplasty (PK). Methods: This is a retrospective case series reporting three eyes (three patients) of with newly formed corneal NV after corneal transplantation. All eyes had pre-existing corneal NVs and were high risk corneal graft rejection cases. One percent topical bevacizumab was started immediately after corneal NV formation post-PK. Topical bevacizumab was kept at twice weekly throughout the follow-up period. Results: Regression of corneal NV without donor graft invasion was noted in all three patients (100%). Duration of topical bevacizumab use was 13 to 36 months. All three corneal grafts (100%) remained clear and no signs of graft rejection were noted for the period of observation. There were no associated systemic or ocular adverse effects. Conclusion: Long-term use of topical 1% bevacizumab may be a safe and efficient treatment for corneal NVs and prevention of graft rejections after corneal transplantation.


Sign in / Sign up

Export Citation Format

Share Document